Connor Clark & Lunn Investment Management Ltd. Has $31.26 Million Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Connor Clark & Lunn Investment Management Ltd. decreased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 27.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,696,875 shares of the company's stock after selling 646,704 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.79% of Hims & Hers Health worth $31,256,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of HIMS. Nisa Investment Advisors LLC grew its holdings in shares of Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock valued at $37,000 after purchasing an additional 1,603 shares in the last quarter. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company's stock worth $72,000 after acquiring an additional 3,507 shares during the last quarter. CWM LLC raised its holdings in Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company's stock valued at $110,000 after buying an additional 1,054 shares during the period. Van ECK Associates Corp purchased a new stake in shares of Hims & Hers Health during the second quarter valued at approximately $111,000. Finally, Amalgamated Bank raised its stake in shares of Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company's stock valued at $133,000 after purchasing an additional 2,354 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 188,888 shares of the firm's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the transaction, the chief executive officer now owns 33,502 shares of the company's stock, valued at approximately $487,789.12. This trade represents a 84.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Oluyemi Okupe sold 11,609 shares of the firm's stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.60, for a total transaction of $169,491.40. Following the completion of the transaction, the chief financial officer now directly owns 181,469 shares in the company, valued at approximately $2,649,447.40. This represents a 6.01 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,056,183 shares of company stock worth $21,501,682. 17.71% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on HIMS shares. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Tuesday, November 5th. Piper Sandler restated a "neutral" rating and issued a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Bank of America cut Hims & Hers Health from a "buy" rating to an "underperform" rating and decreased their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research note on Wednesday, November 6th. Finally, Needham & Company LLC initiated coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a "buy" rating and a $24.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of "Hold" and an average target price of $20.71.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded down $1.74 during midday trading on Wednesday, reaching $21.79. 18,344,971 shares of the stock were exchanged, compared to its average volume of 9,423,281. Hims & Hers Health, Inc. has a twelve month low of $7.51 and a twelve month high of $30.44. The company has a 50 day simple moving average of $20.08 and a 200 day simple moving average of $19.07. The stock has a market capitalization of $4.76 billion, a P/E ratio of 49.34 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $401.56 million during the quarter, compared to analysts' expectations of $382.20 million. During the same period in the previous year, the company earned ($0.04) EPS. The company's revenue for the quarter was up 77.1% on a year-over-year basis. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.